These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 32487444)
1. Malignant insulinoma: 18F-DOPA and 68Ga-DOTATATE PET/CT and treatment with 177Lu-DOTATATE. Erhamamcı S; Sager S; Asa S; Uslu L; Akgun E; Sonmezoglu K Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):383-386. PubMed ID: 32487444 [No Abstract] [Full Text] [Related]
2. Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome. Novruzov F; Mehmetbeyli L; Aliyev JA; Abbasov B; Mehdi E Clin Nucl Med; 2019 Jun; 44(6):e415-e417. PubMed ID: 30789400 [TBL] [Abstract][Full Text] [Related]
3. Is it possible NET-redifferentiation after chemotherapy? Ergül N; Çermik TF; Dursun N Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):31-34. PubMed ID: 31122816 [TBL] [Abstract][Full Text] [Related]
4. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy. Acar E; Çapa Kaya G; Durak H Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172 [TBL] [Abstract][Full Text] [Related]
12. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Ong GS; Henley DE; Hurley D; Turner JH; Claringbold PG; Fegan PG Eur J Endocrinol; 2010 May; 162(5):1001-8. PubMed ID: 20164213 [TBL] [Abstract][Full Text] [Related]
13. Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor. Makis W; McCann K; Riauka TA; McEwan AJ Clin Nucl Med; 2015 Nov; 40(11):880-4. PubMed ID: 26359564 [TBL] [Abstract][Full Text] [Related]
14. Ectopic insulinoma diagnosed by 68Ga-Exendin-4 PET/CT: A case report and review of literature. Zhang X; Jia H; Li F; Fang C; Zhen J; He Q; Liu M Medicine (Baltimore); 2021 Apr; 100(13):e25076. PubMed ID: 33787590 [TBL] [Abstract][Full Text] [Related]
15. Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies. Makis W; McCann K; Buteau FA; McEwan AJ Clin Nucl Med; 2015 Feb; 40(2):162-5. PubMed ID: 25243941 [TBL] [Abstract][Full Text] [Related]
18. Application of Ga(68) -DOTA-exendin-4 PET/CT to localize an occult insulinoma. Cuthbertson DJ; Banks M; Khoo B; Antwi K; Christ E; Campbell F; Raraty M; Wild D Clin Endocrinol (Oxf); 2016 May; 84(5):789-91. PubMed ID: 26562613 [No Abstract] [Full Text] [Related]
19. 68Ga-DOTATATE PET/CT imaging for insulinoma in MEN1 patient with endogenous hyperinsulinemic hypoglycemia: A case report. Liu Y; Zhao X; Zhang J; Wang J; Zhang Z; Dai M; Wang N; Jing F; Wang T; Tian W Medicine (Baltimore); 2022 Aug; 101(34):e30252. PubMed ID: 36042606 [TBL] [Abstract][Full Text] [Related]
20. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]